P. Palumbo, S. Ditlevsen, A. Bertuzzi, A. De Gaetano

MATHEMATICAL MODELING OF THE GLUCOSE-INSULIN SYSTEM: A REVIEW PAPER

R. 11-09 2011

P. Palumbo – BioMatLab, IASI “A. Ruberti”, National Council of Researches, UCSC Largo A. Gemelli 8, 00168 Rome, Italy. Email:pasquale.palumbo@iasi.cnr.it.

S. Ditlevsen – Department of Mathematical Sciences, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen, Denmark. Email:susanne@math.ku.dk.

A. Bertuzzi – IASI “A. Ruberti”, National Council of Researches, Viale Manzoni 30, 00185 Rome, Italy. Email:sandro.bertuzzi@iasi.cnr.it.

A. De Gaetano – BioMatLab, IASI “A. Ruberti”, National Council of Researches, UCSC Largo A. Gemelli 8, 00168 Rome, Italy. Email:andrea.degaetano@biomatematica.it.

ISSN: 1128–3378
Mathematical modeling of the glucose-insulin system: a Review paper

Pasquale Palumbo, Susanne Ditlevsen, Alessandro Bertuzzi and Andrea De Gaetano

October 2, 2011

P. Palumbo and A. De Gaetano are with BioMatLab, IASI “A. Ruberti”, National Council of Researches, UCSC Largo A. Gemelli 8, 00168 Rome. Email: pasquale.palumbo@iasi.cnr.it, andrea.degaetano@biomatematica.it

A. Bertuzzi is with IASI “A. Ruberti”, National Council of Researches, Viale Manzoni 30, 00185 Rome. Email: sandro.bertuzzi@iasi.cnr.it

S. Ditlevsen is with Department of Mathematical Sciences, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen. Email: susanne@math.ku.dk

1 Introduction

The glucose-insulin system offers one of the clearest and simplest examples of homeostatic control in the organism. The level of glucose in blood needs to be kept within a narrow range. Since it represents the main metabolic substrate, or energy source, for brain tissue, abnormally low glucose concentrations give rise to anxiety, tremors, aggressiveness, obfuscation, coma and eventually death. On the other hand, excessive plasma glucose concentrations produce microvascular damages (notably in the retina and kidney) and neural damages, leading among others to blindness and chronic renal insufficiency. The way the body controls glycemia seems deceptively simple. Essentially a single hormone (insulin) is secreted by the $\beta$-cells of the pancreas in response to rising glucose concentrations (hyperglycemia). Insulin effects include increasing peripheral tissue glucose uptake (mainly by the muscle and fat tissues) and decreasing spontaneous glucose output by the liver. When insulin secretion by the pancreas is insufficient or absent, the clinical picture of Type 1 Diabetes Mellitus (T1DM) results; when insulin is secreted in normal, or supranormal amounts, but it is ineffective in lowering glycemia to normal levels, Type 2 Diabetes Mellitus (T2DM) is said to be present. A number of hormones contribute to rescuing the organism from hypoglycemia (adrenalin, glucagon, growth hormone, cortisol): however, since in clinical practice the situation of interest is normally inappropriately high glycemia, concentrating attention on the response to hyperglycemia by insulin seems
justified, at least as a first modeling approach. We may therefore consider, as a first approximation, a simplified system in which a single metabolite (glucose) is controlled by a single hormone (insulin). This system will have to maintain glycemia in the absence of food intake, and will have to suppress hyperglycemia rapidly after meals, without incurring in dangerous hypoglycemias. We see therefore that the glucose-insulin system could be viewed, at least approximately, as a feedback control with a controller (the pancreas) and multiple effectors (muscle, liver, fat tissue), but where the only state variables of interest are glycemia and insulinemia. The present review has the goal of situating the biomedical problem of the glucose-insulin homeostasis from a physiological and clinical viewpoint, then describing the main combined experimental-modeling tools which are currently employed in investigating the behavior of the control system in individuals or populations. In the following sections the following points will be tackled in succession.

Next section will describe the maneuvers or perturbation experiments which have been devised in the past 30 years or so in order to produce experimental data from which a simplified model of the homeostatic control could be identified (IVGTT, OGTT, EHC). In this context, several models designed to interpret the data generated from these maneuvers will be reviewed.

A third section will present models which attempt to describe the way in which the pancreas as a whole releases the hormone insulin, reproducing the essential features of the complicated release mechanics, which produces clearly measurable plasma insulinemia oscillations.

A fourth section will finally address models developed to offer the physician some glimpse on the possible long-term evolution of the disease Diabetes, depending on the comparative evaluation of short term (minutes to hours) control of glucose by means of insulin secretion, and long-term (months to years) evolution of the beta-cell population and its replicating ability in the face of potential glucose toxicity.

2 Short term glucose-insulin models

Short term modeling concerns the glucose-insulin dynamics after an external perturbation such as a glucose bolus injection (Intra-Venous Glucose Tolerance Test, IVGTT), an oral glucose consumption (Oral Glucose Tolerance Test, OGTT) or continuous glucose and insulin infusions like the Euglycemic Hyperinsulinemic Clamp (EHC), within a relatively short time period of a few hours. These clinical experiments, and the mathematical models aiming at their physiological interpretations, have raised a lot of interest in the last decades since they allow to estimate a set of key markers of developing T2DM. Besides inferring a more accurate knowledge of the regulatory mechanisms which rule the glucose-insulin homeostasis, short term mathematical models may be fruitfully linked to clinical protocols in order to compute the glucose effectiveness or the insulin sensitivity of a given subject.
2.1 The Intra-Venous Glucose Tolerance Test

The IVGTT is a clinical experiment where a glucose bolus is rapidly injected intra-venously into a subject. Glucose and insulin samples are acquired in the following 3 hours during which glycemia and insulinemia return to their basal values. The glucose injection is modeled as an instantaneous change in the plasma glucose concentration. In healthy subjects the glucose induced pancreatic response of insulin release consists of two contributions: a first phase release, which is a quick response to a sudden change in glycemia, and a second phase release, which occurs some ten minutes after the bolus injection. The first phase is standardly modeled as an instantaneous change in the plasma insulin concentration. The second phase is described by the model equations, and the difference among the many existing mathematical models are evaluated by their ability to capture correctly the observed dynamics.

2.1.1 The Minimal Model

The early linear models of the glucose-insulin homeostasis, which have been validated by means of an IVGTT, date back to Bolie [12] and the Ackerman’s research group [1, 2, 33] in the sixties. However, the most famous and still greatly widespread model used in clinical assessments, such as the estimate of the insulin sensitivity index, is the so-called Minimal Model (MM), proposed by Bergman and collaborators in the late seventies [6]. For a historical review see [7, 8]. The MM is composed of two separate parts: one describing the dynamics of the glucose uptake after the external stimulus, regarding the insulin concentration as a known forcing function; the other describing the dynamics of the pancreatic insulin release in response to the glucose stimulus, with the glucose concentration regarded as a known forcing function. The model equations for the glucose dynamics are:

\[
\frac{dG}{dt} = -(p_1 + X(t))G(t) + p_1G_b, \quad G(0) = G_b + \Delta_G, \\
\frac{dX}{dt} = -p_2X(t) + p_3(I(t) - I_b), \quad X(0) = 0.
\]

This is a two-compartment model: the first equation refers to the plasma glucose concentration \(G(t)\), the second refers to a remote compartment for the insulin. The physiological assumption is that the insulin-dependent glucose uptake does not directly depend on the plasma insulin concentration \(I(t)\), but on the insulin concentration in the remote compartment, through the auxiliary function \(X(t)\), whose dynamics depends on the plasma insulinemia. \(\Delta_G\) is the instantaneous change of glycemia due to the glucose bolus injection.

The glucose kinetics of the MM allows to compute some important markers of insulin efficacy, which are widely used to diagnose. Among these markers the most important is the insulin sensitivity index, defined as the quantitative influence of basal insulin concentration to increase the glucose effectiveness at steady state, [6]:

\[
S_I = \left. \frac{\partial}{\partial I_b} \left[ -\frac{\partial}{\partial G} \frac{dG}{dt} \right] \right|_{\text{steady state}} = \frac{p_3}{p_2}. \tag{2}
\]
The success of the MM in clinical applications is mostly due to the ability of providing these important markers as a by-product of the model identification procedure.

The second part of the MM concerns the insulin kinetics and consists of a single compartment model, [80]:

$$\frac{dI}{dt} = -n(I(t) - I_b) + \gamma t [G(t) - h]^+, \quad I(0) = I_b + \Delta I.$$  

The insulin kinetics exhibits a linear clearance rate $n$, and an Insulin Secretion Rate (ISR) modeled by a time-varying forcing function, which is motivated by the hypothesis that the effect of circulating hyperglycemia on the rate of pancreatic insulin secretion is proportional both to the hyperglycemia attained and to the time elapsed from the glucose stimulus. The insulin kinetics of the MM is thus necessarily associated to the IVGTT procedure, since the initial experimental time plays a crucial role in assessing the ISR. Therefore the model cannot be used for other purposes, such as a multi-boli experiment, or during glucose infusions. Parameter $h$ is the target glycemia which the actual plasma glucose concentration needs to exceed to stimulate the second-phase pancreatic insulin production. The first phase insulin release is modeled by $\Delta I$. The identification procedure thus has to estimate 4 parameters ($n, \gamma, h, \Delta I$).

2.1.2 Beyond the Minimal Model

The MM has played a crucial role in modeling the glucose-insulin system and it still is of practical use in many clinical settings. Nevertheless, many criticisms have been raised in the last decade. Some questionable physiological assumptions are that the pancreas is able to linearly increase its rate of insulin secretion with time, or the introduction of a non-observable remote compartment to model the insulin effect on the insulin-dependent glucose uptake. The main drawbacks are the lack of mathematical coherence of the model and the lack of robustness in the parameter identification procedure. Both drawbacks are strongly related to the assumption of two distinct parts: the glucose-insulin system is an integrated physiological system whose model should be meaningful as a whole. From a mathematical point of view, it has been proved in [25] that the MM is not coherent, since it does not admit a steady-state solution (corresponding to the basal glycemia/insulinemia), but allows an unbounded increase of the state variables for a reasonable set of model parameters. This is mainly due to the time-varying term and the values the target glycemia $h$ assumes according to data, which are smaller than the measured basal glycemia. This drawback clearly affects the estimate of the insulin sensitivity index also, since it is defined as a steady-state index, but is estimated by use of a mathematical model which does not admit a steady-state solution.

The identification procedure is split into two steps: first the recorded insulin concentration is used as input data to derive the glucose kinetics parameters, then the recorded glucose is used as input data to derive the insulin kinetics parameters. According to this double step identification procedure, one state variable, say glucose, is fitted by using the noisy insulin measurements as a true input function, and the opposite for the insulin
system. This strategy decouples the glucose-insulin regulatory system, disregarding the feedback effects of the state variables. By splitting the two subsystems we may estimate coefficients for one segment (by optimally fitting the relative data), which are not the ones which would generate an optimal approximation to the whole data set if the interaction between the two subsystems were allowed.

In 2000 the following Delay Differential Equation (DDE) model was proposed, [25]:

\[
\frac{dG}{dt} = -b_1 G(t) - b_4 I(t) G(t) + b_7, \quad G(t) \equiv G_b, \quad t \in [-b_5, 0), \quad G(0) = G_b + b_0,
\]

\[
\frac{dI}{dt} = -b_2 I(t) + \frac{b_6}{b_5} \int_{t-b_5}^{t} G(\tau) d\tau, \quad I(0) = I_b + b_3 b_0,
\]

(4)

with \(b_3\) the first-phase insulin concentration increase per mM increase in glucose concentration at time zero due to the injected bolus. The following elements are different from the MM:

- the glucose-insulin system is considered as a whole, with the glucose-insulin dynamics coupled together; accordingly, there is a single step identification scheme;

- no remote compartments mediating the insulin-dependent glucose uptake are present. An insulin-dependent glucose uptake like in (4) was suggested also in an early paper [47];

- the DDE model is no more time-varying. The pancreatic ISR is proportional to the average value of the glucose concentration in the \(b_5\) minutes preceding time \(t\): Thus, it can be validated by an IVGTT, but it is not constrained to that clinical framework. The model is suitable also for multi-boli injections or glucose/insulin infusions.

This model has positive bounded solutions for any physically admissible set of parameters and initial conditions. Moreover, it has a unique positive equilibrium point, corresponding to the basal glycemia/insulinemia, and this point is asymptotically stable, globally within the set of positive initial conditions. The model has also been fitted and validated by means of a standard IVGTT procedure on real data.

It is remarkable that removing the remote (unobservable) compartment, the insulin sensitivity index may be computed without referring to steady state values:

\[
S_I = \frac{\partial}{\partial I} \left[ -\frac{\partial}{\partial G} \frac{dG}{dt} \right] = b_4; \quad (5)
\]

thus, \(S_I\) is provided by the estimate of a single parameter \((b_4)\).

After [25], a great deal of DDE models followed (see, e.g. [5, 30, 41, 42, 43, 48, 52, 53, 90]), most of them referring to long-term frameworks.

Model (4) has been further modified and validated by data [52, 53]. In [52] a family of DDE models is presented, close to the one published in [41]. It introduces general delays, both in the insulin action on tissue glucose uptake and in the glucose action on pancreatic
insulin secretion. A further important difference with most of other previous models is that the insulin-independent glucose uptake may be trivially reduced to a constant term. Of course, this is an approximation, since the brain and the nerve cells which rule the insulin-independent glucose uptake cannot use glucose in case of severe deficiency of glucose. Nevertheless, such a starvation situation is rare and not relevant in an IVGTT experimental protocol. This idea dates back to the pioneering work of [47], but has been forgotten up to the early nineties, where [76] described the long-term glucose-insulin oscillations. This will be discussed in Section 3.

In [52] it is shown that the whole family of models has positive bounded solutions and a unique steady-state solution for any physically admissible setting of both parameters and initial conditions. Stability analysis has been carried out for a pair of significative models from the family: one with discrete delays, the other with continuous delays. In both cases necessary and sufficient conditions are given for the local asymptotic stability of the steady-state solution, which are easily verified over a wide range of realistic parameter values.

Different discrete-delay models from the family have been validated in [53] by data from 40 healthy subjects undergoing an IVGTT. The best fitting model according to the Akaike Criterion resulted to be a Single Delay Model (SDM), with a constant insulin-independent glucose uptake:

\[
\begin{align*}
\frac{dG}{dt} &= -K_{xgI}G(t)I(t) + \frac{T_{gh}}{V_G}, \\
\frac{dI}{dt} &= -K_{xi}I(t) + \frac{T_{iGmax}}{V_I}f(G(t - \tau_g)), \\
f(G) &= \frac{G}{G^*}^\gamma \frac{1}{1 + \left(\frac{G}{G^*}\right)^\gamma}.
\end{align*}
\]

Here \(V_G, V_I\) are the glucose and insulin distribution volumes, respectively. A single explicit delay \(\tau_g\) refers to the control action exerted by glucose on pancreatic insulin secretion, which is expressed by means of a saturable sigmoidal function. No explicit delay in the insulin action on the glucose uptake seemed necessary to explain the observed time series. Initial conditions are:

\[
\begin{align*}
G(t) &= G_b, \quad t \in [-\tau_g, 0), \\
G(0) &= G_b + \Delta_G, \quad \Delta_G = \frac{D_g}{V_G}, \\
I(0) &= I_b + \Delta_I, \quad \Delta_I = I_{Dg}\Delta_G.
\end{align*}
\]

The SDM has been fitted and compared to the MM. The free parameters to be estimated are \(K_{xgI}, K_{xi}, V_G, \gamma, \tau_g, I_{Dg}\), since \(G^*\) and \(V_I\) are set a priori; \(D_g, G_b, I_b\) are measured and \(T_{gh}, T_{iGmax}\) come out from steady-state computation.

Besides a more accurate precision in the parameter estimates in terms of a smaller Coefficient of Variation (CV), the SDM results to be particularly suitable to estimate the insulin sensitivity index which is provided by a single parameter related to the insulin-independent glucose uptake, \(S_I = K_{xgI}\). Indeed, 40 out of 40 subjects showed identifiable \(K_{xgI}\) (CV < 52%) from the SDM, whereas only 20 out of 40 in the MM. Therefore, the SDM apperas to be theoretically sound and robust in practice, and can routinely be considered for the determination of insulin sensitivity from the IVGTT. Free software for
estimating the SDM parameters is available from the authors’ website:
http://www.biomatematica.it/bibif/bibif.html.

2.2 The Oral Glucose Tolerance Test

In the OGTT, plasma glucose and insulin concentrations are measured at time 0, 30, 60, 90, and 120 min, following an oral glucose load of 75 g. C-peptide must also be measured to compute indexes of the insulin secretion. The OGTT is a simple clinical test currently used to aid diagnosis of glucose intolerance and T2DM.

The OGTT mimics the physiological conditions of the glucose/insulin system more closely than the EHC or the IVGTT. However, the analysis of the OGTT data by a mathematical model is affected by the complication that the time course of the delivery to plasma of exogenous glucose and even the total amount of glucose delivered are unknown. In fact, the rate of appearance, Ra, of exogenous glucose in plasma is influenced by several factors: the rate of gastric emptying of ingested glucose, the extent of absorption during the intestinal transit, glucose amount used by gut as energy substrate, and hepatic uptake. Moreover, gut-derived hormones, secreted in response to glucose delivery to the small intestine, markedly increase the insulin secretion with respect to that observed after an intravenous glucose infusion that produces the same elevation of plasma glucose (incretin effect).

Experimental determinations of the rate of appearance of ingested glucose in plasma have been obtained using a double tracer technique by Ferrannini et al. [31, 32]. The Ra was found to have a similar profile in healthy subjects and diabetic patients, and 73-76% of the oral load was recovered in the circulation in the 3.5-h study period. Ra data during an OGTT or a meal test (MTT) were reported by other groups (for instance, see [23, 50, 91]).

The rate of gastric emptying and the small intestine transit time appear to be main factors in determining glucose Ra [91]. Data of gastric retention of glucose (dose fraction retained vs. time) were fitted by a power exponential function and the rate of glucose delivery into the duodenum was computed [68]. A 5% retention of the glucose load was found to depend on interdigestive phase and estimated to occur at about 130 min and 193 min for a load of 50 and, respectively, 100 g.

Mathematical models, developed with the aim of describing the kinetics of the glucose/insulin system during an OGTT or an MTT, and estimating parameters of clinical interest, are reviewed in the following. Attention is focused on some of the more recent contributions. Methods and models used for the analysis of tracer data have not been considered in the present review.

2.2.1 The oral glucose minimal model

The OGTT minimal model [15] extends to the oral test the basic model proposed for the IVGTT, with the modification that glucose administration does no longer appear as a bolus dose D in the initial condition of the equation for glucose kinetics, but as an input function
that specifies the rate of appearance of oral glucose in plasma. The OGTT minimal model has also been used in conjunction with models of C-peptide secretion (see next section).

The model describes the kinetics of the plasma glucose concentration \( G \) (basal value, \( G_b \)), and of the insulin action, \( X \). Model equations are as follows:

\[
\frac{dG}{dt} = -(p_1 + X(t))G(t) + p_1 G_b + \frac{Ra(t)}{V_G}, \quad G(0) = G_b, \\
\frac{dX}{dt} = -p_2 X(t) + p_3 (I(t) - I_b), \quad X(0) = 0,
\]

where \( I \) is the plasma insulin concentration (basal value, \( I_b \)). Insulin concentration data, assumed to be error-free, are used to construct an input function of the system. \( Ra \) is the rate of appearance of oral glucose in plasma, and \( p_1, p_2, p_3, \) and \( V_G \) are parameters with the same meaning as in the IVGTT minimal model. Using the definition of insulin sensitivity given in (2), in [15] it is proposed to compute the \( S_I \) by suitably exploiting the area-under-the-curve (AUC) from time \( t = 0 \) to \( t = \infty \), so that:

\[
S_I = \frac{p_3}{p_2} = \frac{AUC(X)}{AUC(I - I_b)}.
\]

The integrals in the AUCs are computed by taking into account the OGTT measurements throughout the test. Computations make use of a trivial linear relationship where \( Ra \) forces the glucose excursion above its basal value, and of the assumption that glucose and insulin concentrations achieve the pretest basal values at the end of the test.

As this last requirement is not usually satisfied in the clinical setting, parametric descriptions of the rate of appearance were evaluated [21]. The approach chosen was that of representing the \( Ra \) in (8) by a piecewise linear function with a given number (\( n \)) of break points:

\[
Ra(t) = \begin{cases} 
\alpha_i + \frac{\alpha_i - \alpha_{i-1}}{t_i - t_{i-1}}(t - t_{i-1}) & t_{i-1} \leq t \leq t_i, \quad i = 1, \ldots, n \\
0 & \text{otherwise}
\end{cases}
\]

with \( t_0 = 0 \) and \( \alpha_0 = 0 \) (\( Ra(0) = 0 \)). The \( \alpha_i \) values are to be estimated from the glucose concentration data. The \textit{a priori} identifiability of model parameters was shown to be guaranteed provided that \( p_1 \) and \( V_G \) are assumed to be known. Taking \( V_G = 1.7 \text{dl·kg}^{-1} \) and \( GE = 0.024 \text{dl·kg}^{-1}·\text{min}^{-1} \), the method was applied to data from a MTT on normal subjects [21]. To achieve a reasonable \textit{a posteriori} identifiability, the AUC of the reconstructed \( Ra \) was constrained to be equal to \( fD \) (with \( f = 0.86 \)). Moreover, adopting a Bayesian estimation procedure, the rate constant \( p_2 \) that governs the kinetics of insulin action was taken to be normally distributed with mean 0.03 min\(^{-1} \) and CV = 20%. In this way, for each subject, the insulin sensitivity, the parameter \( p_2 \), and the piecewise-linear reconstruction of the \( Ra \) were estimated. The \( S_I \) estimates, derived from a long (420 min) and a short (120 min) oral test were compared with those obtained from an intravenous test.

The performance of the model proposed in [21] in estimating insulin sensitivity and \( Ra \) time course was evaluated by comparing the estimates with those obtained by a reference
tracer technique [22]. The tracer and the non-tracer models were applied to a mixed meal test on normal subjects with data measured up to 420 min. The tracer method provided data on the distribution over the subject population of the model parameters, so allowing to refine the a priori fixed parameters. Substantially similar assumptions were done to guarantee the actual identifiability of the model. The estimates obtained by the non-tracer method were compared by correlation with those obtained by the tracer method ($r = 0.86$ for the $S_I$), whereas lower values of the correlation were found with other indexes of insulin sensitivity, such as HOMA and QUICKI.

To further assess the ability of the oral glucose minimal model in estimating the insulin sensitivity, the OGTT estimates were compared with those provided by the gold standard test, the EHC [23], see Section 2.3. Subjects with normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) underwent both a labeled EHC and a labeled OGTT (OGTT data collected up to 360 min). The data were analyzed by the labeled and the non-labeled OGTT minimal models. Correlation between clamp-derived and OGTT-derived insulin sensitivity was found to give $r = 0.81$ with the non-labeled data and $r = 0.70$ with the labeled data. The insulin sensitivity estimated by the non-labeled OGTT on these subjects was $S_I = 8.08 \pm 0.89 \times 10^{-4} \text{dl} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} \cdot (\mu \text{U/ml})^{-1}$.

### 2.2.2 OGTT models that include minimal models of insulin secretion

A minimal model of C-peptide secretion was proposed by Breda et al. [13]. C-peptide or ISR is represented as the sum of two components related to the glucose concentration (static component) and, respectively, to its rate of change (dynamic component):

$$\text{ISR}(t) = V_1 (SR_s(t) + SR_d(t)),$$

where $V_1$ is the volume of C-peptide central (accessible) compartment. $SR_s$ and $SR_d$, that may be expressed for instance as $\text{pM} \cdot \text{min}^{-1}$, are modeled as follows. The static component, related essentially to the “provision” of new insulin according to the Grodsky model [36], is defined by setting $SR_s(t) = Y(t)$, where $Y$ obeys the equation:

$$\frac{dY}{dt} = \alpha (-Y(t) + \beta [G(t) - h]), \quad Y(0) = 0.$$  

with $\alpha$, $\beta$ and $h$ constant parameters. The dynamic component is related to the insulin stored in the $\beta$-cells in a readily releasable form [36], and is expressed as:

$$SR_d(t) = \begin{cases} 
  k(G(t))\dot{G}(t) & \dot{G}(t) > 0 \\
  0 & \dot{G}(t) \leq 0
\end{cases}$$

where

$$k(G) = \begin{cases} 
  K_d \left(1 - \frac{G - G_h}{G_t - G_h}\right) & G_h \leq G \leq G_t \\
  0 & \text{otherwise}
\end{cases}$$

9
with $K_d$ and $G_t$ model parameters. The parameters in (11)–(13), that provide the input for the two-compartment model of C-peptide kinetics by Van Cauter et al. [88], were estimated from the data of C-peptide concentration and provide sensitivity indexes for the $\beta$-cell function. The static sensitivity index, $\Phi_s$, and the dynamic index, $\Phi_d$, have the following expressions:

$$\Phi_s = \beta, \quad \Phi_d = K_d \left(1 - \frac{G_{\text{max}} - G_h}{G_t - G_b}\right),$$

(15)

where $G_{\text{max}}$, assumed to be smaller than $G_t$, is the maximal glucose concentration observed during the experiment. A global index of $\beta$-cell sensitivity to glucose was also defined as

$$\Phi = \Phi_s + \frac{\Phi_d(G_{\text{max}} - G_h)}{\text{AUC}(G - h)} \simeq \frac{k_{01}\text{AUC}(CP_1)}{\text{AUC}(\Delta G)},$$

(16)

where $CP_1$ is the C-peptide concentration in the central compartment and $k_{01}$ is the rate constant of elimination from this compartment [88].

Using the above model, different OGTT protocols extended over five or four hours and with a different number of samples were compared on NGT and IGT subjects with respect to a reference protocol with 22 samples [13]. In a more recent review paper [20], the insulin sensitivity, the $\beta$-cell function as measured by the sensitivity indexes defined in (15) and (16), the disposition index $\text{DI} = \Phi \cdot S_I$, and the hepatic insulin extraction, were determined on young and elderly individuals and compared with the indexes evaluated by the IVGTT. In the study [4], $\Phi$ was found to be $20.7 \pm 3.0 \times 10^{-9}$ in diabetic patients vs. $52.6 \pm 4.1 \times 10^{-9}$ min$^{-1}$ in controls.

A different approach to derive parameters that characterize the $\beta$-cell function was proposed by Mari et al. [45]. The model represents the relationship between glucose concentration and C-peptide or ISR as the sum of two components. The first component, $S_g(t)$, incorporates a $\beta$-cell dose-response relationship, $f(G)$, which is a nonlinear function of glucose concentration, and a modulating factor that is a function of time and accounts for a possible potentiation effect upon insulin secretion:

$$S_g(t) = \exp[Q(t)]f(G(t)).$$

(17)

$Q(t)$ is modeled as a generic piecewise linear function of time constrained to have zero mean in the time interval of the data, and the quantity $P(t) = \exp[Q(t)]$ is denoted as the potentiation factor. The function $f(G)$, defined in such a way that $f(G) > 0$ for $G > 0$ and $f(0) = 0$, was proposed to have the form

$$f(G) = \frac{p_3G + (p_4 - p_3)}{[\log(\cosh[p_1(G - p_2)]) - \log(\cosh(p_1p_2))] / p_1 + \tanh(p_1p_2)G}$$

(18)

where the parameter $p_2$ is a “threshold” glucose level at which the slope of $f(G)$ changes from the initial value $p_3$ to the final value $p_4$, and $p_1$ determines the curvature around $p_2$. 

10
The second component of the ISR is defined as $S_d(t) = p_d dG/dt$ for $dG/dt > 0$ and zero if $dG/dt \leq 0$, so the total ISR is given by $S(t) = S_p(t) + S_d(t)$.

The time course of plasma glucose concentration, to be given as input function to the insulin secretion model, is provided by a simple model of glucose kinetics,

$$\frac{dG}{dt} = -kG(t) + R(t)$$

(19)

where the rate constant $k$ was set to 0.012 min$^{-1}$, and the function $R(t)$ was represented as a piecewise linear function to be estimated from the data. The secretion model was coupled to the C-peptide kinetic model [88], to predict the C-peptide concentration time-course to be compared with the data.

The estimation of the unknown quantities (the parameters $p_1 - p_4$ of $f(G)$, $p_d$, and the values of $R(t)$ and $Q(t)$ at the chosen times) requires a rather complex approach based on a regularization procedure. The β-cell glucose sensitivity is determined as the mean slope of the dose-response function, $f(G)$, whereas $p_d$ represents a rate sensitivity. In [45], the model was used to analyze data from a multiple-meal test over 14-15 h on control subjects and T2DM patients. The β-cell glucose sensitivity, the rate sensitivity, and the excursion of the potentiation factor were markedly reduced in the diabetic patients with respect to controls.

To evaluate the effects of incretins on the β-cell function, an OGTT and an isoglycemic intravenous test were performed on subjects with normal and impaired glucose tolerance [49]. In the NGT group, the β-cell glucose sensitivity was found to increase from $99 \pm 20$ in the intravenous test to $156 \pm 28$ pmol·min$^{-1}$·m$^{-2}$·M$^{-1}$ in the oral test, whereas the rate sensitivity was not significantly changed. The same behavior was found in the IGT group. The time course of the potentiation factor was significantly delayed in the IGT with respect to NGT subjects. A similar approach was followed to quantify separately the impairment in the incretin effect related to obesity, and to the impaired glucose tolerance or T2DM [50].

By using the hepatic catheterization technique, the hepatic blood flow and the insulin and C-peptide concentrations were measured in the femoral artery and the hepatic vein of healthy controls, obese, and T2DM subjects [85]. A circulatory model for the whole-body kinetics was used. For the hepatic compartment, the equations were written in terms of the steady-state mass flux through the liver, with the inputs from the portal vein (pancreatic secretion) and the hepatic artery, and the output in the hepatic vein. The estimates of ISR showed an hypersecretion in obese subjects and a reduced secretion in the diabetic subjects. The hepatic insulin extraction, found to be higher in diabetic than in control subjects, was also estimated. Data were used to validate a previously proposed mathematical model of β-cell insulin secretion during an OGTT [79].

### 2.2.3 OGTT Models that explicitly include the effect of incretins

Brubaker et al. [14] proposed a model that incorporates several factors that contribute to the observed response to the oral glucose load. The model parameters are indicated as
The rate of glucose delivery to duodenum, $D_G$, was taken to decline linearly with time:

$$D_G(t) = \begin{cases} 
0 & t < t_0 \\
(k_1 - k_2 t) & t_0 \leq t \leq t_{max} 
\end{cases}$$

and $D_G(t) = 0$ for $t > t_{max}$, the time such that $k_1 - k_2 t_{max} = 0$ ($t_0$ set to 5 min). The intercept $k_1$ and the slope $k_2$ were chosen in order to have an AUC of $D_G$ from 5 min to $t_{max}$ smaller but close to the oral dose of glucose. The rate of glucose delivery to duodenum was assumed to control the release of the incretins, represented by a single plasma concentration $Inc$ that obeys the equation

$$\frac{d}{dt} Inc(t) = -k_3 [Inc(t) - Inc_b] + k_4 D_G(t),$$

where the subscript “b” denotes basal values, $k_3$ was set to 0.1 min$^{-1}$, and $k_4$ was estimated from experimental data [68].

The time course of the rate of oral glucose appearance, $Ra$, was established on the basis of the data reported by Ferrannini et al. [31, 32] and has the form

$$Ra(t) = \begin{cases} 
0 & t < t_0 \\
k_5 (t - t_0)^{k_6} \exp[-k_7 (t - t_0)] & t \geq t_0 
\end{cases}$$

where the coefficients $k_5$-$k_7$ were chosen in order to have an AUC of $Ra$ from 5 to 300 min smaller but close to the AUC of $D_G$.

The hepatic glucose balance $H_G$, that represents the difference between hepatic glucose production and glucose uptake from the mesenteric circulation, was expressed as

$$H_G(t) = H_{G,b} + k_8 (G_b - G) I + k_9 \left( \frac{1}{GI} + \frac{1}{(G_b I_b)} \right).$$

The second term in the right hand side of (23) represents a primary regulatory factor that reduces hepatic glucose release when glycemia increases. If a severe hypoinsulinemia occurs, the regulatory action represented by the third term intervenes to increase hepatic glucose release. The plasma insulin concentration, $I$, obeys the equation

$$\frac{dI}{dt} = -k_{10} I + k_{11} Inc_b(t) + k_{12} G^{1.3} + k_{13},$$

where the stimulatory effect of incretins is modeled by the linear term, whereas the coefficient $k_{13}$ represents additional stimulators or inhibitors of the insulin secretion.

The kinetics of plasma glucose concentration is modeled as

$$\frac{dG}{dt} = -k_{14} G(t)^{1.3} - k_{15} I(t) + \frac{1}{V_G} H_G(t) + \frac{1}{V_G} Ra(t) + k_{16} \frac{d}{dt} I(t),$$

where the negative terms in the right hand side specify the dependence on glucose and insulin of the rate of glucose uptake, whereas the last term was empirically introduced to sharpen the peak in glucose concentration following glucose entry into the circulation. Model parameters were adjusted to fit literature OGTT data with doses of 50 g and 100 g, and the model prediction of an IVGTT was also obtained.
2.3 Euglycemic Hyperinsulinemic Clamp

The gold standard for investigating and quantifying insulin resistance is the EHC, and was proposed in [24]. It measures the amount of glucose necessary to compensate for an increased insulin level without causing hypoglycemia, i.e. it intends to “clamp” the glucose concentration at a prespecified level. It is the most widely used experimental procedure for the determination of insulin sensitivity, in spite of its labor-intensive execution, due to the simple interpretation which is usually attributed to the obtained results. The favor with which the EHC is viewed stems in part from the belief that while mathematical models of the glucose insulin system make untenable assumptions, the EHC approach is relatively assumption-free, or model independent.

In its usual form the patient is followed under insulinization for two hours, but often the EHC is continued for 4–6 hours. Through a peripheral vein a priming dose of short-acting human insulin is given during the initial 10 min in a logarithmically decreasing manner, in order to raise acutely the plasma insulin to the desired level. Thereafter, insulin is infused at 10-120 mU per m$^2$ per minute. To compensate for the insulin infusion, glucose is infused to maintain blood glucose levels between 5 and 5.5 mmol/l. The glucose and insulin levels are monitored every 5 min and every 20 min, respectively, and the rate of glucose infusion is adjusted following the algorithm in [24].

The rate of glucose infusion during the last 30–60 minutes of the test determines insulin sensitivity. If high levels (7.5 mg/min or higher) are required, the patient is diagnosed insulin-sensitive. Low levels (4.0 mg/min or lower) indicate that the body is insulin-resistant. Levels between 4.0 and 7.5 mg/min are not definitive and suggest impaired glucose tolerance, an early sign of insulin resistance.

In general, insulin resistance is an expression of the imbalance between the amount of pancreatic insulin, delivered in response to a glucose load, and the levels of plasma glucose reached. To obtain the same plasma glucose concentration, higher levels of plasma insulin are necessary in insulin-resistant subjects than in normal controls. The clamp, as usually employed, yields easy-to-compute indices, which are commonly used as measures of insulin resistance. The M value is defined as the average glucose infusion rate over the period of the last 30–60 minutes of the insulin infusion. The ratio M/I is the ratio of the M value to the average plasma insulin concentration during the same period. If a two-step clamp is performed, i.e. the insulin infusion is increased at some point during the procedure, the $\Delta M/\Delta I$ ratio is defined as the increment of M observed over the corresponding increment of I produced by raising the insulin infusion rate. The use of these indices, however, does make two fundamental assumptions: first, that at the end of the insulin infusion the experimental subject is at steady state with regard to glucose uptake rate; and second, that glucose uptake rate is linearly increasing with increasing insulinemia, either throughout the insulin concentration range (when using the M/I index) or between successive insulin concentrations reached in the two-step clamp (when using the $\Delta M/\Delta I$ index). These assumptions are however only a first approximation of the real state of things.
2.3.1 A mathematical model

To explain the oscillations of glycemia $G(t)$ occurring in response to the hyperinsulinization $I(t)$ and to the continuous glucose infusion at varying speeds, the following model was proposed in [57],

\[
\begin{align*}
\frac{dG}{dt} &= T_{gx} (t-\tau) + T_{gh} (t) \frac{G(t)}{V_g} - T_{xg} 0.1 + G(t) \left( K_{xg} I(t - s) \int_0^\infty \omega(s) I(t - s) ds \right) G(t) , \\
\frac{dI}{dt} &= T_{ig} G(t) + T_{ix} (t) \frac{V_i}{V_i} - K_{xi} I(t) , \\
\end{align*}
\]

(26)

where

\[ T_{gh}(t) = T_{gh}^* \exp \left( -\lambda G(t) \int_0^\infty \omega(s) I(t-s) ds \right) , \quad T_{gh}(0) = T_{ghb} = T_{gh}^* e^{-\lambda G_b I_b} \]

(27)

and

\[ \omega(s) = \alpha^2 s e^{-\alpha s} ; \quad T_{gx}(s) = 0 \quad \forall s \in [-\tau, 0] ; \quad T_{ix}(0) = T_{ixb} . \]

(28)

Initial conditions are: $G(0) = G_b$ and $I(t) = I_b \quad \forall t \leq 0$. The input functions $T_{gx}(t)$ and $T_{ix}(t)$ are the glucose and the insulin infusion rates, and $V_g$ and $V_i$ are the volume of distribution for glucose and insulin, respectively. $K_{xg}$ is the insulin-dependent first-order rate constant for glucose tissue uptake, and $K_{xi}$ is the first-order rate constant for insulin removal from plasma.

The variation of glucose concentration is due to the external glucose infusion rate, to liver glucose output $T_{gh}(t)$, and to delayed-insulin-dependent as well as insulin-independent glucose tissue uptake. Here, $T_{xg}$ is the maximal insulin-independent rate constant for glucose tissue uptake. Infused glucose raises glycemia after a delay $\tau$ due to the necessity of equilibrating the intravenously infused quantity throughout the distribution space. The net hepatic glucose output is assumed to be equal to $T_{ghb}$ at the beginning of the experiment and to decrease toward zero as glycemia or insulinemia levels increase. Serum insulin, in a delayed fashion depending on its transport to the periphery and to the subsequent activation of cellular membrane glucose transporters, affects glucose clearance through (26) and glucose synthesis rate through (27).

The kernel $\omega(s)$ represents the density of metabolic effect at time $t$ for unit serum insulin concentration at time $t - s \ (s \leq t)$. It increases to a maximum at $s = 1/\alpha$, then decreases monotonically and asymptotically to zero. This represents the metabolic effect of insulin having to reach the tissues and activate intracellular enzymatic mechanisms (hence a delay in maximal action on glucose metabolism), and that natural breakdown of insulin induces progressive loss of effect of the hormone. A high $\alpha$-value determines a concentrated kernel, corresponding to a fast-rising, fast-decaying effect of insulin on peripheral tissues.

The insulin-independent glucose tissue uptake process is modelled as a Hill function rapidly increasing to its (asymptotic) maximum value $T_{xg}$; thus for glycemia values near 2
mM the insulin-independent glucose tissue uptake is already close to its maximum. This represents the aggregated apparent zero-order glucose utilization mechanism at rest (mainly the brain and heart), with the mathematical and physiological necessity that glucose uptake go to zero as glucose concentration in plasma approaches zero. The variation of insulin concentration is due to the external insulin infusion, to glucose dependent pancreatic insulin secretion and to the apparent first-order insulin removal from plasma.

Eq. (27) represents the rate of net hepatic glucose output, taking its maximal value $T_{gh}^*$ at zero glucose and zero insulin and decaying monotonically with increases in both glucose and effective insulin plasma concentrations.

Steady-state conditions are used to decrease the number of free parameters to be estimated. At steady state, before the start of the clamp, we have

$$T_{xg} = \left( \frac{T_{ghb}}{V_g} - K_{xgl}I_bG_b \right) \frac{0.1 + G_b}{G_b}; \quad T_{iG} = \frac{K_{xi}I_bV_i}{G_b}. \quad (29)$$

Therefore the parameters $T_{xg}$ and $T_{iG}$ are completely determined by the values of the other parameters.

### 2.3.2 Stochastic models

As an alternative to the above deterministic model, a stochastic model was proposed in [59]. Assume that the underlying tissue glucose uptake process is not smooth, subject as it is to a variety of metabolic and hormonal influences, which change over time. In fact, tissue glucose uptake is determined not only by the varying concentrations of certain hormones (e.g. cortisol or growth hormone) and by the rhythm of food intake, events which take place over periods of hours, but also by sudden changes in physical activity or emotional stresses induced by thought processes. Thus, the rate constant $K_{xgl}$ is likely to exhibit irregular oscillations over time.

Let the parameter $K_{xgl}$ vary randomly as $(K_{xgl} - \xi(t))$, where $\xi(\cdot)$ is a gaussian white-noise process. The system noise $\xi(t)dt$ can be written as $\sigma dW(t)$, where $\sigma > 0$ is the diffusion coefficient and $W$ is a Wiener process, see chapter 1 in this volume. By incorporating the $K_{xgl}$ variation into the deterministic model without delays, we obtain the following (Itô) stochastic differential equation

$$dG(t) = \left[ \frac{(T_{gx}(t) - \tau_g) + T_{gh}(t)}{V_g} - T_{xg} \frac{G(t)}{0.1 + G(t)} - K_{xgl}G(t)I(t) \right] dt$$

$$+ \sigma G(t)I(t)dW(t), \quad (30)$$

$$dI(t) = \left[ \frac{T_{iG}G(t) + T_{ix}(t)}{V_i} - K_{xi}I(t) \right] dt,$$

with

$$T_{gh}(t) = T_{gh}^* e^{-\lambda G(t)I(t)}; \quad T_{gh}(0) = T_{ghb} = T_{gh}^* e^{-\lambda G_b I_b} \quad (31)$$
and initial conditions $G(0) = G_b, I(0) = I_b$. All coordinates of this process stay positive.

Considerable simplification can be obtained in the stochastic model by only modeling the dynamics after insulin has reached its steady-state, as proposed in [58]. Then a one-dimensional model is sufficient, and insulin concentration is assumed constant and equal to the average insulinemia $I^*$. Consider the glucose dynamics described by

$$dG(t) = \left( \frac{T_{gx}(t - \tau_g) + T_{ghnet}}{V_g} - K_{xg}I^*G(t) \right) dt + \sigma I^*G(t)dW_t,$$

(32)

where $G(t_0) = G_0$ is the recorded glycemia at time $t_0 = 40$ min for the given subject. The glucose infusion rate $T_{gx}(\cdot)$ is approximated by a smoothed step function, whose values $\lambda_1, ..., \lambda_m$ change at times $0 = \nu_1 < \nu_2 < \cdots < \nu_m$. It is defined as:

$$T_{gx}(t) = \sum_{\nu_j \leq t} \frac{(\lambda_j - \lambda_{j-1}) \cdot (t - \nu_j)^5}{\nu_j + (t - \nu_j)^5}, \quad t > 0, \quad \lambda_0 = 0, \quad j = 1, ..., m,$$

(33)

where $T_{gx}(t) = 0$ for every $t \in [-\tau_g, 0]$, $t = 0$ being the instant in which the insulin infusion start (to be distinguished from the $t_0$ instant, which equals 40 min). The exponent of $(t - \nu_j)$ in (33) has been chosen to be the minimum integer such that the average of $\{|T_{gx}(\nu_j) - \lambda_j|\}_{j=1, ..., m}$ is less than $3 \times 10^{-3}$.

The EHC procedure attempts to reach steady-state with a constant blood glucose concentration and infusion rate. Thus, it is reasonable to assume that the process is stationary towards the end of the experiment, which can be used to determine one parameter from the others. Thus, from the $G^*$ expression above, an estimate of $T_{ghnet}$ is given by

$$T_{ghnet} = K_{xg}I^*V_g - T_{gx}^*.$$

$T_{gx}(\cdot)$ only depends on $t$ and is bounded between 0 and 5 mmol/min/KgBW, approximately corresponding to the pump infusion of 50% glucose in water at a maximal rate of 100 ml in a subject of small size (50 Kg). Thus, the model (32)-(33) fulfills the usual Lipschitz condition and linear growth bound, so that it has a unique $t$-continuous solution (see chapter 1 in this volume). Since $T_{gx}(\cdot)$ changes over time as an external forcing function, the distribution of $G(t)$ will depend on $t$ and thus not be stationary.

When $T_{gx}(\cdot)$ is constant, the stationary distribution of $X_\infty := \lim_{t \to \infty} X_t$ is an Inverse Gamma distribution with shape parameter $1 + 2K_{xg}/\sigma^2I^*$ and scale parameter $2(T_{gx} + T_{ghnet})/V_g(\sigma I^*)^2$ (if $X$ is Inverse Gamma, then $1/X$ is Gamma). The asymptotic mean glycemia is $G^* = (T_{ghnet} + T_{gx}^*)/(K_{xg}I^*V_g)$, where $T_{gx}^*$ is the mean glucose infusion rate over the last hour of the experiment. This can be used as an alternative measure of insulin sensitivity.

3 Insulin secretion and oscillations

Mathematical modelling of glucose-stimulated pancreatic insulin secretion is a challenging research topic that has involved much work in the last decades. Among the first references we find the pioneering work of Grodsky [36], who first distinguished a first phase of insulin
release, due to the insulin packets immediately releasable as a consequence of a rapid increase in glycemia, from the second phase related to the potentiation effect that occur during a sustained glucose stimulation. In addition to the minimal models of the pancreatic insulin release, considered in Section 2.2.2, more detailed models are considered in the present Section. These models account for the biochemical mechanisms (the insulin granule dynamics) that eventually determine the insulin release from the β-cell, adopting a more or less coarse scale of details according to the available literature.

Strictly connected to the insulin release is the phenomenon of the apparently regular oscillations of insulinemia, that occur at different time scales (low and high frequency oscillations), and are possibly tied to the known pulsatility in insulin secretion. This matter will be developed in the second half of the Section.

3.1 Insulin Granule Dynamics

Insulin granule trafficking in pancreatic β-cells has been investigated in recent years by using fluorescent proteins that are targeted to secretory granules and allow the real-time imaging of granules in living cells [66]. A β-cell contains 10,000 – 13,000 granules of diameter ∼350 nm, each containing ∼1.6 amol of insulin plus other polypeptides and smaller molecules. Most granules belong to a large “reserve pool”, around 600 are docked with the plasma membrane, with 50–100 granules in a pool of immediate release, and other ∼1500 are located close to cell surface [66, 29]. Granule exocytosis requires the fusion of granule membrane with plasma membrane and the formation of a pore that connects granule lumen to extracellular space. Incomplete fusion and kiss-and-run exocytosis may also occur.

As found by early observations in vitro and in vivo, stimulation by a rapid and large increase in the extracellular glucose concentration induces a biphasic time course of the ISR with a 5 – 10 min peak, the first phase, followed by a more prolonged second phase. These features were modeled by the early mathematical models [36, 16]. Recent experimental data from mouse and rat β-cells showed that only 1 – 2 granules/min per β-cell are released at a glucose concentration around 3 mM, and 20 – 30 granules/min per cell are released at the peak of the first-phase insulin secretion after a step increase in glucose, with a total secretion of about 680 granules in 50 min (for instance, see [75]).

In a first pathway of stimulus-secretion coupling (triggering pathway), the glucose stimulus increases the ATP/ADP ratio, which induces closing of the K\(_{\text{ATP}}\) channels and depolarization of cell membrane. The resulting Ca\(^{2+}\) influx through the voltage-sensitive Ca\(^{2+}\) channels raises the cytosolic free calcium concentration, [Ca\(^{2+}\)]\(_{c}\), so promoting the exocytosis of insulin granules. Still not completely characterized are the mediators of the amplifying pathway, that augments the efficacy of Ca\(^{2+}\) in stimulating the insulin secretion [37, 29, 38].
3.1.1 Mathematical models

Shibasaki et al. [70] used a model based on a three-dimensional random walk process to simulate the movement of insulin granules in an idealized β-cell. The introduction of a bias, that represented the recruitment of granules to plasma membrane, produced the second-phase response. The first phase was simulated by assuming that the randomly distributed granules had an increased density near the plasma membrane, so representing a pool of immediately releasable granules. Simulation results were in agreement with the observation that cAMP promotes exocytosis by both increasing the size and accelerating the refilling of the pool of immediate release.

The model proposed in [11] defines a pool, $I$, of free proinsulin and a pool, $V$, of free granule membrane material, not yet enclosing proinsulin. Moreover, four pools of insulin granules were considered: the reserve pool ($R$), the docked granules ($D$), the immediately releasable granules ($D_{IR}$), and the granules fused with cell membrane ($F$). Model equations are as follows:

$$\frac{dI}{dt} = -kI(t)V(t) - \alpha_I I(t) + b_I,$$  \hspace{1cm} (34)

$$\frac{dV}{dt} = -kI(t)V(t) - \alpha_V V(t) + b_V + \sigma F(t - \tau_V),$$  \hspace{1cm} (35)

$$\frac{dR}{dt} = kI(t)V(t) - \gamma(t)R(t),$$  \hspace{1cm} (36)

$$\frac{dD}{dt} = \gamma(t)R(t) - k^+ [C_T - D_{IR}(t)]D(t) + k^- D_{IR}(t),$$  \hspace{1cm} (37)

$$\frac{dD_{IR}}{dt} = k^+ [C_T - D_{IR}(t)]D(t) - k^- D_{IR}(t) - \rho(t)D_{IR}(t),$$  \hspace{1cm} (38)

$$\frac{dF}{dt} = \rho(t)D_{IR}(t) - \sigma F(t).$$  \hspace{1cm} (39)

In (34), $k$ is an aggregation rate constant, $\alpha_I, \alpha_V$ are degradation rate constants, and $b_I, b_V$ denote, respectively, the rate of proinsulin biosynthesis and the production rate of granule membranes. The last term in the right-hand side of (35) accounts for the contribution to granule membrane formation of the recycling of membrane material, with $\sigma$ the rate constant of the fusion process and $\tau_V$ the time interval required for recycling. The variable $\gamma$ in (36) represents the processes by which granules are irreversibly translocated from trans-Golgi network to plasma membrane, and it is dependent on the glucose concentration, $G$, according to (40). The pool $D_{IR}$ is formed through the binding of docked granules to L-type Ca$^{2+}$ channels, with $C_T$ denoting the pool of total Ca$^{2+}$ channels and $k^+_I, k^-_I$ the rate constants of association and, respectively, dissociation. The factors that promote granule fusion are represented by $\rho$, and $\sigma F(t)$ in (39) is the number of granules releasing insulin in the unit time at time $t$ in a single β-cell.
The equations that relate glucose stimulus to the quantities, $\gamma$ and $\rho$, that govern granule trafficking are as follows:

\[
\frac{d\gamma}{dt} = \eta [-\gamma(t) + \gamma_b + \psi(t) + h_\gamma(G(t - \tau_G))], \\
\frac{d\rho}{dt} = \zeta [-\rho(t) + \rho_b + h_\rho(\gamma(t))],
\]

where basal value are indicated by the subscript "b", $\eta$ and $\zeta$ are rate constants, and $\psi$ represents factors that induce ATP and calcium oscillations. Glucose activation is modeled by the saturating function $h_\gamma$, with $\tau_G$ the time required by glucose metabolism. So $\gamma$ regulates granule translocation and priming, and through $h_\rho$ regulates granule fusion and the ISR. Glucose thus controls the material flux from $b_I$, $b_V$ to $\sigma F$.

Pedersen et al. [55] proposed a model that reconciles the Grodsky’s threshold distribution hypothesis, concerning the different responsiveness of $\beta$-cells to glucose stimulus, with recent findings on insulin granule dynamics. The following granule pools were defined: mobilized and docked granules are merged into an intermediate pool, $I$; the insulin amount in the readily releasable granules in $\beta$-cells with activation threshold between $g$ and $g + dg$ is defined as $h(g,t)dg$ where $h$ is a density with respect to threshold; $F$ is the size of the fused pool. The equations are

\[
\frac{dI}{dt} = M(G,t) - rI(t) - p^+I(t) + p^- \int_0^\infty h(g,t) dg, \\
\frac{d}{dt} h(g,t) = p^+I(t)\phi(g) - p^-h(g,t) - f^+h(g,t)\theta(G - g), \\
\frac{dF}{dt} = f^+ \int_0^G h(g,t) dg - kF(t) - mF(t).
\]

$M(G,t)$ in (42) is the rate of granule mobilization from the reserve pool to plasma membrane, and is given by

\[
\frac{d}{dt} M(G,t) = [M(G,t) - M_\infty(G)]/\tau,
\]

where $\tau$ is a time constant. $M_\infty(G)$ is an increasing function of glucose concentration regulating granule inflow into the system, and the quantity $mF(t)$ in (44) is the ISR. The parameters $r$, $f^+$, $k$, and $m$ are the rate constants of granule re-internalization, granule fusion, failed release because of the kiss-and-run exocytosis and insulin release. The parameters $p^+$ and $p^-$ regulate the processes of granule priming and de-priming, $\phi(g)$ is the threshold distribution, and $\theta$ the Heaviside function.

Pedersen and Sherman [56] considered the following granule pools: almost docked ($AP$), docked ($DP$), primed ($PF$), and located close to L-type Ca$^{2+}$ channels, immediately releasable granules ($IRP$). A recently described highly calcium-sensitive pool ($HCSP$ [92]),
that also contains releasable granules, was included in the model. Granules in IRP and HCSP may fuse with the plasma membrane, so entering “fused” pools (FIP or FHP), and then enter the “releasing” pools (RIP or RHP). Model equations are as follows:

\[
\frac{d}{dt} \text{IRP}(t) = r_1 \text{PP}(t) - r_{-1} \text{IRP}(t) - f_I(C_{md}(t)) \text{IRP}(t),
\]

(46)

\[
\frac{d}{dt} \text{PP}(t) = r_2 \text{DP}(t) + r_{-1} \text{IRP}(t) - (r_{-2} + r_1) \text{PP}(t),
\]

(47)

\[
\frac{d}{dt} \text{DP}(t) = r_3 \text{HCSP}(t) + r_{-2} \text{PP}(t) - (r_{-3} + r_2) \text{DP}(t),
\]

(48)

\[
\frac{d}{dt} \text{HCSP}(t) = r_4 \text{AP}(t) + r_{-3} \text{DP}(t) - (r_{-4} + r_3) \text{HCSP}(t) - f_H(C_i(t)) \text{HCSP}(t),
\]

(49)

\[
\frac{d}{dt} \text{AP}(t) = r_5 + r_{-4} \text{HCSP}(t) - (r_{-5} + r_4) \text{AP}(t),
\]

(50)

\[
\frac{d}{dt} \text{FIP}(t) = f_I(C_{md}(t)) \text{IRP}(t) - u_2 \text{FIP}(t),
\]

(51)

\[
\frac{d}{dt} \text{RIP}(t) = u_2 \text{FIP}(t) - u_3 \text{RIP}(t),
\]

(52)

\[
\frac{d}{dt} \text{FHP}(t) = f_H(C_i(t)) \text{HCSP}(t) - u_2 \text{FHP}(t),
\]

(53)

\[
\frac{d}{dt} \text{RHP}(t) = u_2 \text{FHP}(t) - u_3 \text{RHP}(t),
\]

(54)

where \( r_i \) and \( r_{-i} \), \( i = 1, \ldots, 5 \), are rate constants of reversible transition between pools, and \( r_5 \) represents a granule inflow from a reserve pool into the almost docked pool. The parameters \( u_2 \) and \( u_3 \) represent irreversible transitions, and \( u_3(RIP + RHP) \) is the number of granules per β-cell releasing insulin in the unit time.

The Hill functions, \( f_I \) in (46) with Michaelis constant equal to 22 µM, and \( f_H \) in (49) with Michaelis constant equal to 2.5 µM, represent the fusion rates from IRP and, respectively, HCSP, as determined by the Ca^{2+} concentrations in the sub-plasma membrane microdomains \((C_{md})\) and in the cytosol \((C_i)\). These concentrations obey the two-compartment system equations:

\[
\frac{dC_{md}}{dt} = -f_{md}J_L(V(t)) - f_{md}B(C_{md}(t) - C_i(t)),
\]

(55)

\[
\frac{dC_i}{dt} = -f_iJ_R(V(t)) + f_vf_iB(C_{md}(t) - C_i(t)) - f_iL(C_i(t)),
\]

(56)

where: \( f_{md} \) and \( f_i \) are constants representing the ratio of free to bound Ca^{2+} in the microdomain and, respectively, the cytosol; \( B \) is the transport rate constant between the
compartments; $f_v$ is the ratio of microdomain to cytosol compartment volume. $L(C_c)$ represents the processes that regulate calcium clearance out of cytosolic compartment. $J_L$ and $J_R$ represent the Ca$^{2+}$ fluxes through the L-type and, respectively, R-type calcium channels, expressed as a function of the plasma membrane potential, $V$, which is the input variable. The two-compartment calcium model captures the presence of the high calcium gradients in the β-cell.

### 3.2 Modeling the glucose-insulin oscillations

In the last decades, there have been published many papers detailing on the occurrence of several modes of oscillations of the glucose-insulin system, trying to construct a theoretical description of the mechanisms responsible for this behavior, considering also whether some external (neural) influence is actually needed to coordinate pancreatic islet activity in order to generate macroscopically evident oscillations [74, 34, 61]. What are usually found are high-frequency pulsatile variations of glycemia and insulinemia with a power spectrum occupying the 5-15 minutes interval [3, 35, 40] and low-frequency spontaneous oscillations (known as ultradian oscillations in the literature), with a period of approximately 50-150min, with their amplitude enhanced upon exogenous glucose administration, from meals [72, 60], continuous enteral nutrition [71] or constant IV infusions [69, 87].

Discontinuous insulin secretion happens at several scales. At the level of a single β-cell, insulin is released as discrete granules, as the final result of the metabolic-electrical activity of the cell, leading to the characteristic behavior known as bursting, with a period of tens of seconds from spike to spike (see [54] and references therein); these simple bursts often cluster in compound bursts, with a period of several minutes [9]; intra-islet synchronization leads to consider compound bursts as produced at the level of a “homogeneous secretory unit”; finally, at the level of the portal vein, it has been widely documented that the overall insulin secretion is resolved in a series of partially overlapping discrete secretory events, [63, 64], at periods of 5 to 15 minutes. It is this last phenomenon that we will hereafter refer to as pulsatile insulin secretion. Since the period of these last discrete secretory events is similar to that of the previously mentioned compound bursts, it has been maintained that compound bursting is responsible for overall insulin pulsatility [9]; nevertheless completely desynchronized compound bursts from a very large number of secretory units would combine to give a generally flat insulin secretion profile, so some additional mechanism is likely to be present in order for evident oscillations to appear.

Models published so far are not able to describe, with a unique mathematical construct, both ultradian and rapid pulsatile oscillations. On one hand, they may offer a high-level mathematical synthetic description of (as yet) unknown or imperfectly understood mechanisms, offering simplified deterministic descriptions of the time course of observed insulinemia, directly relating it to other whole-body state variables (like glycemia), without considering in detail the individual effect of the secretory units (pancreatic β-cells, collected in Langerhans islets) or the actual molecular mechanisms which act within the secretory units themselves. Among the first mathematical models aiming to describe the occurrence of insulin oscillations is the nonlinear ODE model of Sturis et al. [76]. According to the
different shapes of the exogenous glucose infusion, different in silico experiments have been carried on, concerning constant glucose infusions as well as oral glucose administration or multiple meal ingestion, with the aim to provide a plausible mechanism for the genesis of the oscillations. Indeed, the authors suggested that the ultradian oscillations in insulin and glucose concentrations could originate from their reciprocal interaction without postulating an intrapancreatic pacemaker for their existence. The model of Sturis et al. has been the starting point for many DDE models, aiming to replicate the occurrence of long-period glucose-insulin oscillations as coming from a Hopf bifurcation point (see, e.g. \cite{30, 5, 43, 42}). It has to be stressed that the model of Sturis et al. and its DDE versions have been used, especially in the recent years, with the aim of testing the action of pulsatile insulin profiles in (pre)-diabetic patients \cite{81, 30, 89, 90, 93, 17, ?}.

On the other hand, mathematical models have been written, which, based upon rather stronger hypotheses, attempt to incorporate known biochemical mechanisms, operating at the $\beta$-cell level, in as much detail as feasible. Such models can predict single $\beta$-cell pulsatile insulin secretion. When several $\beta$-cells are coupled, the oscillatory response of insulin secretion to oscillating glucose is enhanced. Recent examples of this type of models are provided by \cite{54, 84} where, by suitably exploiting different biochemical assessments combining electrical and calcium dynamics with the glycolitic oscillator \cite{73, 9, 10}, the authors managed to describe the synchronization of intra/inter-islets $\beta$-cells.

In the above mentioned models (the ODE as well as the DDE models), the reproduction of the desired oscillatory regime of their solutions is dependent on identifying appropriate parameter values by means of a (typically numerical) bifurcation study. So far, the model structures and the relative bifurcation assessments have made it so that each model proposed can give rise to only one oscillatory regime (either fast or slow).

A very recent work \cite{51} proposes a different type of theoretical model for pancreatic insulin secretion, able to describe simultaneously rapid pulsatile and ultradian insulin oscillatory regimes, and their response to experimental maneuvers. A rather elementary mathematical model for a single secretory unit is used. While this model is vastly simpler than those proposed by other authors \cite{54, 84, 73, 9, 10}, it incorporates the secretory effect of the known physiological bursting response of aggregates of $\beta$-cells to varying glucose concentrations, without detailing the chain of biochemical events giving rise to this response.

The main difference with respect to previously published models is that the single-unit model is not required to produce any oscillatory behavior per se. Observed whole-body insulinenia oscillations emerge from the aggregated response of the entire population of secretory units, a population which is naturally heterogeneous in terms of reaction thresholds, recovery times and insulin packet size. In order to produce this aggregated behavior, the simple single-unit model is replicated for as many independent secretory units as are simultaneously considered (say, one million different single-unit models corresponding to one million Langerhans islets \cite{39}). No coordination among units is required, beyond what is provided by minute oscillations of glycemia (produced in turn by the combined dynamic effect of the secreted insulin via a model of glucose kinetics). Since the phenomenon of $\beta$-cell synchronization (likely due to the electrical activity of the $\beta$-cell membrane) within
an islet of Langerhans has been well documented [65, 46, 28, 67, 86], the number $N$ of independent secretory units is intended to represent the number of islets (about 1 million [39]) instead of the number of $\beta$-cells (about 1,000 $\beta$-cells per islet, that is 1 billion total). By *independent units* it is meant that no direct control is exerted on a secretory unit either by other units or by neural or endocrine mechanisms, the only connection among the units being the common input signal represented by blood glucose concentration, as sensed by each secretory unit. This is consistent with the experimental literature, which stresses the crucial role of glucose feedback in governing pulsatile insulin secretion [19, 77, 62].

This model assumes that each single secretory unit is able to react to circulating glycemia by ejecting a discrete *packet* of insulin $D_n$, if glycemia exceeds that unit’s secretion threshold $B_n$. As a secretory unit releases its insulin packet, it enters a (relative) refractory state, where further stimulation fails to elicit the release of new hormone. This refractory state is represented by instantaneously increasing that unit’s secretion glycemia threshold to a very high level $R_n$ whence, with time, it exponentially decreases towards its *resting threshold* value $G_n$: $G_n < R_n$. $B_n$ obeys, therefore, the following ordinary differential equation:

$$\frac{dB_n}{dt} = -\alpha_n B_n(t) + \alpha_n G_n + (R_n - B_n(t)) \delta(G(t) - B_n(t)), \quad (57)$$

where $\alpha_n$ is the rate of recovery of sensitivity of the secretory unit, $G(t)$ is the plasma glucose concentration, and $\delta(\cdot)$ is the Dirac delta term specifying instantaneous increase of the threshold to the refractory level $R_n$ upon discharge of insulin.

High values of $G_n$ (with respect to the prevailing glycemas) correspond to secretory units which seldom fire (possibly never), while low values of $G_n$ correspond to secretory units which fire frequently, as soon as they recover from their refractory state, according to their individual rate of recovery $\alpha_n$. Clearly, an increase of glycemia $G(t)$ (corresponding for instance to the post-prandial state) will induce the recruitment of more secretory units from the population of seldom firing units, with a corresponding increase in the secretion of insulin.

It is assumed that $\beta$-cells which are often stimulated will progressively increase the size of their synthetic enzymatic machinery (in the medium term and up to a limit) according to a sigmoid function, so as to deliver larger amounts of insulin. Such phenomenon is known as *potentiation* [44, 45, 83]. This effect is here represented by having the size of the packet of insulin delivered by the $n$-th unit vary according to the following dynamics:

$$\frac{dD_n}{dt} = -k_n D_n(t) + \rho_n \frac{G^{\gamma_n}(t)}{G^{\gamma_n}(t) + \Gamma_n^{\gamma_n}}, \quad (58)$$

with $k_n$ being the insulin packet natural decrease rate, $\rho_n$ the maximal saturating potentiation charging rate, $\Gamma_n$ [mM] the glycemia at which the islet potentiation is half of its maximal rate and $\gamma_n$ the progression with which the potentiation reacts to circulating glucose concentrations (for small $\gamma_n$, a moderate potentiation occurs over a wide glycemic range, while for large $\gamma_n$, abrupt potentiation occurs over a restricted glycemic range). If
plasma glycemia is kept at a high value, the unit is forced to react to such persistent hyperglycemic condition by increasing its insulin packet size, according to (58). It is reasonable to assume that for a typical unit, $\Gamma_n$ is greater than the basal value $G_b$: in this way, small increases of plasma glycemia do not substantially affect potentiation; on the contrary, when $G(t)$ approaches $\Gamma_n$, a faster increase of potentiation occurs, up to a glucose toxicity level, for which a saturating steady state potentiation level is maintained.

By setting once and for all the (hyper-)parameter values, i.e. parameters identifying the distribution from which single-unit structural parameters are sampled, this population model is able to replicate both the ultradian and rapid pulsatile oscillatory regime, in absence of exogenous periodic stimuli, like the clinical experiments detailed in [71, 78]. Moreover, it is also able to replicate the synchronization of both ultradian and rapid pulsatile oscillation to the frequency of exogenous periodic glucose infusions, phenomenon known as entrainment.[78, 62].

4 Long-term diabetes

Models for metabolism in diabetes mellitus, in particular models for the Glucose-Insulin control system, typically span the (short) time along which perturbation experiments (IVGTT or OGTT) are performed and blood concentrations of metabolites are obtained. Longer time spans are used when assessing the response to antidiabetic therapy, during ‘classical’ clinical trials: in this case observation times can arrive to up to four years. It is evident that organizational and economic difficulties essentially prohibit the conduction of long-term experimental studies, where patients are followed for decades in the attempt to identify the mechanism of the development of diabetes. Still, a number of rational, physiology based hypotheses can be made regarding these mechanisms, extrapolating the existing limited-time experimental data. Among such hypotheses, of particular interest are those regarding the variation of the beta-cell mass in a given individual, its sensitivity to glucose toxicity (the assumed effect which high glycemias have in depressing beta-cell net replication rate), and its possible response to therapeutic interventions. The information available in this context is limited also by the fact that reliable non-destructive methods do not yet exist, which allow the quantification of the current size of the beta-cell mass in a given individual.

In this framework, mathematical modeling allows a coherent set of assumptions to be combined in a quantitative way. Even though parameter estimation is essentially impossible, given the timescale over which the development of diabetes mellitus takes place and in particular given the practical impossibility of observing the size of the beta-cell population, useful information can be obtained from a combination of qualitative behavior conclusions and of numerical simulations based upon the assessment of key model parameters from published results.

Not many models regarding the longtime development of diabetes have been published. The main contributions so far can be ascribed to the work of de Winter and colleagues, [27], of Topp and colleagues, [82], and of De Gaetano and colleagues, [26].
The principles at the basis of short term and long term modeling may not be the same. The most common paradigm upon which short term metabolic modeling is built is that of mass action. According to this principle the system under investigation can be represented as a set of interconnected compartments and the flow of material from one another is regulated by simple mass balance considerations. While the validity of this approach seems unquestionable in the short term, extending a mass balance based model by simply reinterpreting time as representing “slow time” (i.e. months to years) instead of “fast time” (i.e. minutes to hours) seems wholly inappropriate. While for instance plasma glucose one minute after clearly depends in a mass balance way on plasma glucose one minute before, the same cannot be said of glucose one month after with respect to glucose one month before. In slow time the mass transfers accumulate and the variable values represent integrated influences. For this reason, this author disagrees with the model proposed by de Winter and associates, which does represent essentially an IVGTT model carried over to slow time.

The model which will be described in subsequent paragraphs was published in 2008 and represents an advancement over a previous model by Topp, [82], with which it shares the basic philosophy.

In T2DM a progressive increase of glycemia is likely determined by progressively increasing insulin resistance at the level of both peripherals tissues and liver. In the face of this increasing insulin resistance, the pancreas is unable to increase its insulin output beyond a certain level. In fact, possibly due to glucose toxicity, replicating ability in the pancreatic beta-cells decreases and eventually beta-cell mass declines, with the eventual development of the frank clinical picture of diabetes. It is therefore essential that a mathematical model for the development of diabetes includes such key variables as beta-cell population, prevailing insulinemia and glycemia, and pancreatic beta-cell replication reserve.

The variation of beta-cell population, indicated as $B(t)$, follows a simple exponential growth:

$$\frac{dB}{dt} = \lambda B(t), \quad B(t_0) = B_0$$

where the parameter $\lambda$ is a function of prevailing glucose levels, through a third order Hill function, and depends on the current pancreatic reserve $\eta$:

$$\lambda(G) = \lambda_{\min} + \eta \frac{x^3}{1 + x^3}, \quad x(G) = x_0 \frac{G}{G_\lambda}$$

In this way higher glucose levels stimulate beta-cell replication, in a way which is consistent with the controller action of the endocrine pancreas. In its turn, however, pancreatic reserve $\eta$ follows a dynamics determined by a natural tendency to be restored, but affected negatively by high prevailing glucose concentrations through a glucose toxicity parameter $K_{\eta G}$.

$$\frac{d\eta}{dt} = -K_{\eta G} G(t) \eta(t) + T_\eta, \quad \eta(t_0) = \eta_0.$$
Prevailing glucose and insulin levels are obtained by setting at equilibrium one of many possible models of fast glucose-insulin control:

\[ G = \frac{\gamma}{\rho + I}, \quad I = h(G)I_{\text{max}}B. \quad (62) \]

In fact, it can be shown that many such fast models, when taken at equilibrium, give rise to the same algebraic slow model. In this sense, the slow model proposed is a representative of an entire equivalence class of possible fast homeostatic models. The function \( h \) introduces the nonlinear, indeed saturable, dependency of insulin secretion upon glucose levels:

\[ h(G) = \frac{(G^{\nu_h})^{\nu_h}}{1 + (G^{\nu_h})^{\nu_h}}. \quad (63) \]

The equations reported above express the main ideas underlying the model. Full details can be found in a previous publication [26].

Given the practical impossibility of estimating parameter values from data sets, the parameter values with which the model has been made to run have been derived from a careful scrutiny of the existing literature, resulting in several instances what were perceived to be contradictions in the reported results. Just to make one example, are reports of beta-cell apoptosis rates from cadaver preparations were felt to be excessive, and incompatible with other reported results on beta-cell replication rates in that if apoptosis were as high and replication as low as reported, then everybody would become type 1 diabetic in a very short time. In this case, the reported replication rate was assumed to represent both replication and apoptosis at equilibrium in the living human.

One of the main successes of the model has been its ability to predict what is commonly clinically observed, and for which a direct biologic explanation had been long searched for: the rapid development of diabetes after many years of essentially normal glycemias. The model predicts that prolonged very mild hyperglycemia, such as can be observed due to progressively increasing insulin resistance (due to accumulation of fat tissue, dietary habits and lack of physical activity) progressively undermines pancreatic replication reserve. Until pancreatic reserve is still sufficient to allow for progressively increasing ISRs, no major increase in blood glucose is observed. A point is reached, however, when pancreatic of replication rates cannot sustain further increase in insulin secretion, at which point glycemia starts to rise, glucose toxicity is intensified and the entire compensation mechanism fails, with the apparent sudden development of frank diabetes. No specific determinants of the crisis need therefore to be looked for: the very nonlinear structure of the compensation mechanism determines an apparent normality for a long time in the face of actually worsening homeostatic derangement, followed by a rapidly accelerated decompensation once reserves have been exhausted.
5 Conclusions

Partly due to the high social impact of Diabetes (particularly of T2DM in industrialized societies, given its link with obesity), partly due to the potential simplicity in describing mathematically a two-variable system, the glucose-insulin homeostatic control has been one of the most studied biomedical problems from the point of view of modelling, attempting to summarize the main features of the system being studied, as well as to motivate the continuing effort spent for modelling the system, in terms of improvement in identification of the mechanisms involved, of more reliable prediction of the future condition of a given patient, of more effective prevention or delay of the occurrence of frank diabetes mellitus, and of safer automatic insulin infusion devices for T1DM patients.

Given the vastity of the field and the large number of important results, which many authors contributed over the past four decades or so, it has been impossible to present all facets of the problem. In particular, many bottom-up, molecular mechanistic models have attempted to describe the biochemical chain of reactions giving rise to insulin secretion at the beta-cell level, and glucose uptake at the tissue level. These are not presented in this article.

Throughout the paper, a leading thread has been that while every model is an approximation to reality, these models interpret actual medical observations on the basis of shared or debated assumptions, offering to the critical reader a handle for further hypotheses and experimentation. In their counterpoint and in their chorality the voices of the many authors who worked in this field compose a very interesting chapter in the field of the application of mathematics to medical problems.

References


R.N., Lovejoy, J.C. (eds.) The minimal model approach and determination of glucose
tolerance, pp. 3-50. LSU Press (1997)

J., Green, M., Boston, R. (eds.) Mathematical modeling in nutrition and health.
Kluwer Academic/Plenum (2001)

[9] Bertram R., L. Satin, M. Zhang, P. Smolen, A. Sherman, Calcium and glycolisis

[10] Bertram R., A. Sherman, A calcium-based phantom bursting model for pancreatic

Metab., 293: E396-E409 (2007)

[12] Bolie, V.W.: Coefficients of normal blood glucose regulation. J. Appl. Physiol. 16,
783-788 (1961)

erance test minimal model indexes of β-cell function and insulin sensitivity. Diabetes,
50, 150-158 (2001)

model of the oral glucose tolerance test illustrating the effects of the incretins. Ann.

in normal subjects: a minimal model index. J. Clin. Endocrinol. Metab., 85, 4396-
4402 (2000)


[17] Chen, C.-L., Tsai, H.-W., Modeling of physiological glucose-insulin system on normal
and diabetic subjects, Computer Methods and Programs in Biomedicine, 97, 130-140
(2010)

[18] Chen, C.-L., Tsai, H.-W., Wong, S.-S., Modeling of physiological glucose-insulin dy-


